Compare XERS & CEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | CEVA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 642.7M |
| IPO Year | 2018 | 2000 |
| Metric | XERS | CEVA |
|---|---|---|
| Price | $7.15 | $21.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.43 | ★ $34.20 |
| AVG Volume (30 Days) | ★ 2.1M | 817.0K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $266,137,000.00 | $107,530,000.00 |
| Revenue This Year | $44.37 | $4.41 |
| Revenue Next Year | $27.87 | $14.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.05 | 5.55 |
| 52 Week Low | $3.14 | $18.23 |
| 52 Week High | $10.08 | $38.94 |
| Indicator | XERS | CEVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 44.01 |
| Support Level | $6.85 | $21.56 |
| Resistance Level | $7.24 | $23.56 |
| Average True Range (ATR) | 0.29 | 0.98 |
| MACD | 0.09 | 0.37 |
| Stochastic Oscillator | 84.94 | 61.43 |
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.